Morphic Holding, Inc.
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF…
Biotechnology
US, Waltham [HQ]
Cash Flow Statement
7 Sheets · From 2023 to 2017Configuration
In Million USD. Margins, Growth Rates In %
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Operating Cash Flow (OCF) | -15.00 | 76.00 | -41.00 | -45.00 | -83.00 | -100.00 | -112.00 | |
| Operating Cash (Net) | -15.00 | 76.00 | -41.00 | -45.00 | -83.00 | -100.00 | -112.00 | |
| Accounts Receivable | - - | - - | -3.00 | -3.00 | 5.00 | 1.00 | - - | |
| Accounts Payable | - - | - - | 3.00 | -1.00 | - - | -1.00 | 3.00 | |
|
Working Capital
|
- - | - - | - - | - - | - - | - - | - - | |
| Change | - - | 98.00 | -1.00 | -13.00 | -11.00 | -72.00 | 8.00 | |
| Other WC | - - | 97.00 | -2.00 | -11.00 | -14.00 | -73.00 | - - | |
| Investing Activities | ||||||||
| Used Cash (Net) | - - | - - | -135.00 | 8.00 | -113.00 | -56.00 | -341.00 | |
| Capital Expenditure | - - | - - | -2.00 | - - | -1.00 | - - | -1.00 | |
| Purchases of Investments | - - | - - | -296.00 | -145.00 | -244.00 | -238.00 | -764.00 | |
| Sale/Maturity of Investment | - - | - - | 162.00 | 154.00 | 132.00 | 182.00 | 423.00 | |
| Property, Plant, Equipment (P&PE) | - - | - - | -2.00 | - - | -1.00 | - - | -1.00 | |
| Acquisitions (Net) | - - | - - | 133.00 | -8.00 | 112.00 | - - | 340.00 | |
| Other Investing Activities | - - | - - | -133.00 | 8.00 | -112.00 | - - | -340.00 | |
| Financing Activities | ||||||||
| Used Cash (Net) | -20.00 | -89.00 | -93.00 | -38.00 | -266.00 | -45.00 | -453.00 | |
| Debt Repayment | - - | - - | - - | - - | - - | - - | - - | |
| Dividends Paid | - - | - - | - - | - - | - - | - - | - - | |
|
Common Stock
|
- - | - - | - - | - - | - - | - - | 452 | |
| Issued | - - | - - | 93.00 | 4.00 | 266.00 | 45.00 | 453.00 | |
| Repurchased | - - | - - | - - | - - | - - | - - | - - | |
| Other Financing Activities | 20.00 | 90.00 | - - | 38.00 | 266.00 | 45.00 | 453.00 | |
| Cash Balances | ||||||||
| Begin of Period | 17.00 | 21.00 | 186.00 | 101.00 | 102.00 | 171.00 | 59.00 | |
| End of Period | 21.00 | 186.00 | 101.00 | 102.00 | 171.00 | 59.00 | 59.00 | |
| Change | 3.00 | 165.00 | -84.00 | - - | 69.00 | -112.00 | - - | |
| Non-Cash Balances | ||||||||
| Depreciation and Amortization | - - | - - | - - | 1.00 | 1.00 | 1.00 | 1.00 | |
| Stock Based Compensation | - - | - - | 3.00 | 11.00 | 21.00 | 29.00 | 40.00 | |
| Other | - - | - - | - - | - - | 1.00 | - - | -10.00 | |
| Highlighted metrics | ||||||||
| Free Cash Flow (FCF) | -16.00 | 75.00 | -43.00 | -46.00 | -84.00 | -101.00 | -113.00 | |
| Cash Conversion Cycle (CCC) | - - | - - | 39.00 | 4.00 | -2,475.00 | -1,424.00 | -2,575.00 | |
| Invested Capital | - - | - - | - - | - - | - - | - - | - - | |
|
Other Operating Inflows/Outflows
|
||||||||
| Forex Effect on Cash | - - | - - | - - | - - | - - | - - | - - |